Author:
Kelley Robin Kate,Rimassa Lorenza,Cheng Ann-Lii,Kaseb Ahmed,Qin Shukui,Zhu Andrew X,Chan Stephen L,Melkadze Tamar,Sukeepaisarnjaroen Wattana,Breder Valery,Verset Gontran,Gane Edward,Borbath Ivan,Rangel Jose David Gomez,Ryoo Baek-Yeol,Makharadze Tamta,Merle Philippe,Benzaghou Fawzi,Banerjee Kamalika,Hazra Saswati,Fawcett Jonathan,Yau Thomas
Reference31 articles.
1. Hepatocellular carcinoma;Llovet;Nat Rev Dis Primers,2021
2. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008
3. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study;Lee;Lancet Oncol,2020
4. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial;Yau;Lancet Oncol,2022
5. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med,2020
Cited by
316 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献